Survey of Ophthalmology
Volume 48, Issue 2, Supplement , Pages S21-S24 , April 2003

Retinal Ganglion Cells and Neuroprotection for Glaucoma

  • Leonard A Levin, MD, PhD

      Affiliations

    • Corresponding Author InformationReprint address: Leonard A. Levin, MD, PhD, University of Wisconsin Medical School, 600 Highland Avenue, Madison, WI 53792, USA

References 

  1. The advanced glaucoma intervention study (AGIS) . 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429–440
  2. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma . Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:498–505
  3. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures . Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126:487–497
  4. Balazsi AG, Rootman J, Drance SM, et al.  The effect of age on the nerve fiber population of the human optic nerve. Am J Ophthalmol. 1984;97:760–766
  5. Brubaker R. Targeting outflow facility in glaucoma management. Surv Ophthalmol. 2003;48(Suppl 1):S17–S20
  6. Cantor L. Achieving low target pressures with today's glaucoma medications. Surv Ophthalmol. 2003;48(Suppl 1):S16–S18
  7. Goldberg I. Relationship between intraocular pressure and preservation of visual field in glaucoma. Surv Ophthalmol. 2003;48(Suppl 1):S3–S7
  8. Heijl A, Leske MC, Bengtsson B, et al.  Reduction of intraocular pressure and glaucoma progression (results from the Early Manifest Glaucoma Trial). Arch Ophthalmol. 2002;120:1268–1279
  9. Hernandez MR, Andrzejewska WM, Neufeld AH. Changes in the extracellular matrix of the human optic nerve head in primary open-angle glaucoma. Am J Ophthalmol. 1990;109:180–188
  10. Hernandez MR, Pena JD. The optic nerve head in glaucomatous optic neuropathy. Arch Ophthalmol. 1997;115:389–395
  11. Hernandez MR, Pena JD, Selvidge JA, et al.  Hydrostatic pressure stimulates synthesis of elastin in cultured optic nerve head astrocytes. Glia. 2000;32:122–136
  12. Kass MA, Heuer DK, Higginbotham EJ, et al.  The Ocular Hypertension Treatment Study (a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma). Arch Ophthalmol. 2002;120:701–713 discussion 829–30
  13. Kerrigan LA, Zack DJ, Quigley HA, et al.  TUNEL-positive ganglion cells in human primary open-angle glaucoma. Arch Ophthalmol. 1997;115:1031–1035
  14. Ko ML, Hu DN, Ritch R, et al.  Patterns of retinal ganglion cell survival after brain-derived neurotrophic factor administration in hypertensive eyes of rats. Neurosci Lett. 2001;305:139–142
  15. Ko ML, Hu DN, Ritch R, Sharma SC. The combined effect of brain-derived neurotrophic factor and a free radical scavenger in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000;41:2967–2971
  16. Kwong JM, Lam TT. N-methyl-D-aspartate (NMDA) induced apoptosis in adult rabbit retinas. Exp Eye Res. 2000;71:437–444
  17. Lipton SA. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv Ophthalmol. 2003;48(Suppl 1):S38–S46
  18. Mikelberg FS, Drance SM, Schulzer M, et al.  The normal human optic nerve. Axon count and axon diameter distribution. Ophthalmology. 1989;96:1325–1328
  19. Neufeld AH. Nitric oxide (a potential mediator of retinal ganglion cell damage in glaucoma). Surv Ophthalmol. 1999;43(Suppl 1):S129–S135
  20. Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol. 1997;115:497–503
  21. Neufeld AH, Sawada A, Becker B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci USA. 1999;96:9944–9948
  22. Okisaka S, Murakami A, Mizukawa A, Ito J. Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes. Jpn J Ophthalmol. 1997;41:84–88
  23. Schlamp CL, Johnson EC, Li Y, et al.  Changes in Thy1 gene expression associated with damaged retinal ganglion cells. Mol Vis. 2001;7:192–201
  24. Schori H, Kipnis J, Yoles E, et al.  Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension (implications for glaucoma). Proc Natl Acad Sci USA. 2001;98:3398–3403
  25. Siliprandi R, Canella R, Carmignoto G, et al.  N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina. Vis Neurosci. 1992;8:567–573
  26. Tatton W, Chen D, Chalmers-Redman R. Hypothesis for a common basis for neuroprotection in glaucoma and alzheimer's disease (anti-sapoptosis by alpha-2 adrenergic receptor activation). Surv Ophthalmol. 2003;48(Suppl 1):S25–S37
  27. Tezel G, Wax MB. Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci. 2000;20:8693–8700
  28. Wax MB. Is there a role for the immune system in glaucomatous optic neuropathy?. Curr Opin Ophthalmol. 2000;11:145–150
  29. Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol. 2003;48(Suppl 1):S47–S51
  30. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:2849–2855

PII: S0039-6257(03)00007-9

doi: 10.1016/S0039-6257(03)00007-9

Survey of Ophthalmology
Volume 48, Issue 2, Supplement , Pages S21-S24 , April 2003

Article Tools

* Image Usage & Resolution